Evolus (NASDAQ:EOLS) Trading Down 9.6% – Time to Sell?

Evolus, Inc. (NASDAQ:EOLS) dropped 9.6% during trading on Monday . The stock traded as low as $12.56 and last traded at $12.28. Approximately 206,913 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 592,049 shares. The stock had previously closed at $13.58.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Wednesday, March 5th. Barclays increased their target price on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Wednesday, March 5th.

Evolus Stock Down 11.8 %

The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The firm has a market capitalization of $761.71 million, a PE ratio of -13.16 and a beta of 1.28. The company has a fifty day moving average price of $12.95 and a 200-day moving average price of $14.05.

Institutional Trading of Evolus

A number of large investors have recently made changes to their positions in EOLS. KBC Group NV bought a new position in shares of Evolus in the 4th quarter worth $49,000. IFP Advisors Inc increased its stake in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of Evolus during the 4th quarter worth about $106,000. Rafferty Asset Management LLC acquired a new position in Evolus during the fourth quarter worth $115,000. Finally, Quantbot Technologies LP acquired a new stake in shares of Evolus during the 4th quarter worth about $118,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.